Lisata Therapeutics, Inc. has filed an amendment to its previous report, updating financial statements related to its acquisition of Marea Therapeutics. This amendment, filed on November 12, 2026, is significant as it reflects Lisata's ongoing expansion strategy in the pharmaceutical sector, particularly in therapeutic development.
The filing includes audited combined financial statements of Marea Therapeutics, Inc. and M2 Therapeutics, Inc. for the years ended December 31, 2025, and 2024, as well as interim financial statements for the six months ended June 30, 2026. This update is crucial for stakeholders as it provides a clearer picture of the financial health and operational integration following the merger.
Lisata Therapeutics is categorized under the Standard Industrial Classification (SIC) code 2834, which pertains to Pharmaceutical Preparations. The company trades on the Nasdaq under the ticker symbol LSTA. The latest filing is part of a series of recent submissions, including a 10-Q filed on November 13, 2026, and an S-3 registration statement filed on the same day.
The amendment to the original report, which was first filed on September 17, 2026, noted the completion of the acquisition of Marea Therapeutics. The latest filing aims to provide updated financial information that may affect investors' perceptions and decisions regarding Lisata's future.
With the pharmaceutical industry constantly evolving, this move by Lisata may influence how competitors approach their own growth strategies. The focus on financial transparency and the integration of acquired companies is a critical aspect that industry players will be monitoring closely.
Looking ahead, the filing does not specify what further actions will be taken by Lisata Therapeutics following this amendment. However, the company’s proactive approach in updating its stakeholders indicates a commitment to maintaining clarity and trust in its operations.
Read Next
Manthripragada Vijay Acquires Additional Shares in Onterris
Laws James Acquires Shares in Onterris, Inc. via RSUs
Eightco Holdings CEO Acquires 100,000 Shares of Stock
Eightco CFO Vroman Acquires 15,000 Shares in Stock Transaction
Orchestra BioMed CFO Acquires Shares in Recent Filing
Upwork CFO Erica Gessert Reports Major Stock Transactions




